OptimizeRx (OPRX) Price to Sales (2012 - 2026)

OptimizeRx has disclosed Price to Sales across 15 years of filings, most recently posting 5.25 for Q2 2026.

• In Q2 2026, Price to Sales fell 38.79% year-over-year to 5.25; the TTM figure through Jun 2026 stood at 1.09 (down 54.36% YoY), while the FY2025 annual figure was 2.1, up 115.9% from the prior year.
• Price to Sales came in at 5.25 for Q2 2026 at OptimizeRx, down from 5.94 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 49.16 in Q1 2022 to a low of 2.78 in Q4 2024.
• Average Price to Sales over 5 years is 14.18, with a median of 9.45 recorded in 2023.
• Year-over-year, Price to Sales tumbled 80.93% in 2022 and soared 157.06% in 2025.
• Over 5 years, Price to Sales stood at 15.63 in 2022, then slumped by 41.41% to 9.16 in 2023, then slumped by 69.7% to 2.78 in 2024, then soared by 157.06% to 7.13 in 2025, then dropped by 26.34% to 5.25 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 5.25 in Q2 2026, 5.94 in Q1 2026, and 7.13 in Q4 2025.